par Vandenbossche, Jean Luc 
Référence Revue médicale de Bruxelles, 33, 4, page (273-279)
Publication Publié, 2012-09
Référence Revue médicale de Bruxelles, 33, 4, page (273-279)
Publication Publié, 2012-09
Article révisé par les pairs
| Résumé : | Current treatment of heart failure remains suboptimally implemented, leading to less favorable outcome. Readmission due to decompensation, remains frequent, in about 20% of patients at one month and 50% at six months. Precipitating factors of deterioration are known, including inappropriate drug interactions, and the early detection can be facilitated by simple clinical features (weight, heart rate, dyspnea) that can be confirmed by biomarkers (BNP, Nt-ProBNP). Medical treatment relies upon the proper use of drugs that have been demonstrated efficacious in the randomized clinical trials, and have been proposed in the international clinical guidelines. The basic principle of their titration consists on a gradual increase of the dosage, up to the target dosages, or maximal clinically tolerated dosages. Particular attention shall be paid to renal function and kaliemia, besides clinical parameters ; close monitoring is mandatory along the treatment. |
